University of Warmia and Mazury in Olsztyn

University / College


Location: Olstyn, Poland (PL) PL

ISNI: 0000000121496795

ROR: https://ror.org/05s4feg49

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours) (2022) Kos-Kudła B, Foltyn W, Malczewska A, Bednarczuk T, Bolanowski M, Borowska M, Chmielik E, et al. Journal article Neuroendocrine neoplasms of the small intestine and the appendix - Update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego - uaktualnione zasady diagnostyki i leczenia (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych) (2022) Bednarczuk T, Zemczak A, Bolanowski M, Borowska M, Chmielik E, Cwikla JB, Foltyn W, et al. Journal article Gastroduodenal neuroendocrine neoplasms including gastrinoma - Update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) (2022) Rydzewska G, Strzelczyk J, Bednarczuk T, Bolanowski M, Borowska M, Chmielik E, Cwikla JB, et al. Journal article Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results (2021) Pavel ME, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, et al. Journal article Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study (2021) Pavel ME, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results (2021) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Thanh TXM, et al. Conference contribution Tear fluid collection methods: Review of current techniques (2021) Pieczyński J, Szulc U, Harazna J, Szulc A, Kiewisz J Journal article, Review article Molecular profiling of clear cell myoepithelial carcinoma of salivary glands with EWSR1 rearrangement identifies frequent PLAG1 gene fusions but no EWSR1 fusion transcripts (2021) Skálová A, Agaimy A, Vanecek T, Baněčková M, Laco J, Ptáková N, Šteiner P, et al. Journal article Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results (2020) Pavel ME, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution The eye — a window to cardiovascular diseases (2020) Dąbrowska E, Harazny J, Wolf J, Szulc U, Narkiewicz K Journal article, Review article
1 2 3 4 5